Skip to main content

Table 3 Cases of dedifferentiated endometrioid adenocarcinoma (DEAC) with clinical and pathologic features

From: Dedifferentiated endometrioid carcinoma of the uterus : report of four cases and review of literature

Author

Number of cases

Age, years

Surgical operation (cases)

Stage (cases)

Component of tumor

Marker expression of UC component

Adjuvant treatment (cases)

Survival outcome (cases)

Silva, EG (2006) [3]

25

51 (median) (range: 30–82)

TH+ BSO (24)

I (14)

II (1)

III (6)

IV (4)

Low grade (10–80%) + UC(20-90%)

Keratin (13 out of 15, focal or diffuse) EMA (all)

Neuroendocrine marker (4 out of 15)

Chemotherapy (18)

radiation (4)

DOD (15) (median: 7 months)

AWPD (6)

(6 ~ 8 months)

NA(3)

Shen, Y (2012) [18]

1

51

TH + BSO + PLND

II

Low grade (80%) + UC(20%)

Negative for EMA focally positive for CK7, CK18

Vaginal radiation + chemotherapy (CDDP+ DTX + Taxanes)

NA

Vita, G (2011) [19]

1

45

TH + BSO

IIIA

Low grade (60%) + UC(40%)

Positive for cytokeratins and EMA

Chemotherapy (CDDP + ATC + Taxanes)

NA

Wu, ES (2013) [20]

1

62

NA

NA

NA

NA

Radiation + hormone therapy (Megace alternating with Tamoxifen)

AWPD (3 months)

Berretta, R (2013) [21]

1

67

NA

IV

NA

Positive for keratin and negative for neuronal markers

Chemotherapy (CBDCA + Taxol)

NA

Park, SY (2014) [22]

1

55

TH + USO + PLND

IB

Low grade (40%) + UC(60%)

Focally positive for CK and EMA

Chemotherapy (PTX + CDDP+DOXO)

DOD (7 months)

Li, Z (2016) [15]

13

61 (median)

NA

III/IV (12)

NA

Pancytokeratin (10 out of 13)

Cam5.2 (8 out of 13)

EMA (8 out of 13, weak and patchy)

PAX-8 (1 out of 13)

Chemotherapy and radiation (13)

Recurrence or metastasis within 3 years of diagnosis (12)

Disease-free after 3 years of diagnosis (1)

Soyama, H (2016) [23]

1

41

Supravaginal hysterectomy + USO+partial resection of ileum

IVB

NA

NA

Chemotherapy alone

DOD (7 months)

Rabban (2016) [24]

1

50

TH + BSO+PLND

IA

G1(60%) + UC(40%)

Negative for EMA, keratin, PAX-8

Untreated

Progression after 10 months of surgery

  1. TH total hysterectomy; BSO bilateral salpingo-oophorectomy; PLND pelvic lymph node dissection; DOD die of disease; AWPD alive with progressive disease; USO unilateral salpingo-oophorectomy; NA not available; CDDP cisplatin; DTX docetaxel; ATC anthracycline; CBDCA Carboplatin; PTX paclitaxel; DOXO doxorubicin